The Taiwan Stock Exchange Corporation (TWSE) approved on 7 February the initial listing application of Energenesis Biomedical Co., Ltd. Energenesis was founded in 2012 and obtained the status of a biotechnology company from the Ministry of Economic Affairs in 2015. The company's main business is new drug development, testing and analysis services, and reagent sales.

Energenesis is a Taiwan-based company engaged in the research and development of pharmaceutical innovation, and in September 2022, it filed an IND for its new drug ENERGI-F703, a topical gel for diabetic foot ulcers, with US-based FDA.

On January 19, 2023, the company was notified that its investigational new drug, ENERGI-F703EB, had been notified by FDA's Office of Orphan Drug Development (OOPD) in a letter of approval for Rare Pediatric Disease Designation (RPD). F703EB orphan drug is eligible for the treatment of hereditary epidermolysis bullosa (EB) and will be eligible for a Priority Review Voucher (PRV) once ENERGI-F703EB is launched. At this stage, there are 10 new drugs in the clinical IND preparation process, and a number of international pharmaceutical companies are in the process of licensing.

The company has three strategies for the development of new drugs: 1) Fast: with two new drugs entering phase II in 2017, and two new drugs entering phase III in the US in 2023. 2) Proactive: the patented ENERGI platform, including Parkinson's disease, Alzheimer's disease and cancer malignant disease, has about ten drug development projects in different fields. 3) Accurate: not following the market trend of competing for cancer drugs, but selecting new drugs that require the most "self-healing" wound development, with few competitors in the market, but a large number of patients.

The patented ENERGI technology platform activates AMPK (AMP-activated protein kinase), a key enzyme for cellular energy regulation, to increase cellular energy ATP (adenosine triphosphate) to promote self-healing of injured cells in the body. Therefore, instead of being competitive, the use of "treatment" in the face of competitors can be a multiplier by the fact that self-healing + treatment = recovery.

In order to increase Taiwan's R&D capacity, Energenesis has collaborated with a number of R&D units in Taiwan on a number of projects to accelerate the company's model of using increased cellular capacity and numbers. By providing funding for R&D and combining the R&D expertise of the universities, Energenesis will be able to develop cures and drugs for a variety of diseases, in the hope of leaving its mark for Taiwan-made pharmaceutical products.